• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Karyopharm - oncology

Quote
























anonymous said:
What difference would it make anyway? Share price is in the basement. Issuing another 20 million shares gets you about $15 million before the investment bankers take their fees. That keeps the lights on for 6-8 weeks.
Click to expand...
They could have raised at $9 a share before they did at $5 a share. It’s not like they didn’t know the path ahead. They just can’t find the Emerald City without someone painting them a yellow brick road.
 




















This is a common shell game from an unqualified CEO...look over here, so you don't look at what is actually happening. He knows it.

If these data sets were so compelling, and patients could benefit that greatly from Seli, there would be far faster ways to get trials enrolled and read out.

This is a purposeful delay with hopes they can sell the company on the positive speculation of today of what could be, versus reading the data out and perhaps it is positive, but not earth shattering or practice changing, which would further suppress the share price. How many phase 2 trials fail to reach the same efficacy endpoints in their phase 3?

Fortunately or unfortunately these strategic decisions are not being made by the CEO rather the BOD and the heavy institutional investors.
 




anonymous said:
This is a common shell game from an unqualified CEO...look over here, so you don't look at what is actually happening. He knows it.

If these data sets were so compelling, and patients could benefit that greatly from Seli, there would be far faster ways to get trials enrolled and read out.

This is a purposeful delay with hopes they can sell the company on the positive speculation of today of what could be, versus reading the data out and perhaps it is positive, but not earth shattering or practice changing, which would further suppress the share price. How many phase 2 trials fail to reach the same efficacy endpoints in their phase 3?

Fortunately or unfortunately these strategic decisions are not being made by the CEO rather the BOD and the heavy institutional investors.
Click to expand...
He’s dirty.
 




anonymous said:
This is a common shell game from an unqualified CEO...look over here, so you don't look at what is actually happening. He knows it.

If these data sets were so compelling, and patients could benefit that greatly from Seli, there would be far faster ways to get trials enrolled and read out.

This is a purposeful delay with hopes they can sell the company on the positive speculation of today of what could be, versus reading the data out and perhaps it is positive, but not earth shattering or practice changing, which would further suppress the share price. How many phase 2 trials fail to reach the same efficacy endpoints in their phase 3?

Fortunately or unfortunately these strategic decisions are not being made by the CEO rather the BOD and the heavy institutional investors.
Click to expand...
He’s dirty.
 




anonymous said:
He’s dirty.
Click to expand...
They been doing it since he rode up the golden escalator and proclaimed his vaulted “four pillars” offense. He jumped from pillar to pillar like a Ghana man selling fake Gucci bags on 8th ave. They dangled mds until they couldn’t. They back pocketed mf for a time until it served its purpose as a distraction from Endo failures and trial nightmares. They think we are dumb.
 








anonymous said:
They been doing it since he rode up the golden escalator and proclaimed his vaulted “four pillars” offense. He jumped from pillar to pillar like a Ghana man selling fake Gucci bags on 8th ave. They dangled mds until they couldn’t. They back pocketed mf for a time until it served its purpose as a distraction from Endo failures and trial nightmares. They think we are dumb.
Click to expand...


True. This is now an all or nothing play, as the vast majority of our institutional investors are deeply underwater. I am shocked that the banks have not removed RP and more board members in favor of their own people to attempt to right the ship. The only think that is preventing that from happening is this a pimple on a flies but in terms of their massive portfolios...meaning they don't really care all that much. If it happens it happens...if it doesn't it will be hard to even find on their balance sheets.
 




anonymous said:
True. This is now an all or nothing play, as the vast majority of our institutional investors are deeply underwater. I am shocked that the banks have not removed RP and more board members in favor of their own people to attempt to right the ship. The only think that is preventing that from happening is this a pimple on a flies but in terms of their massive portfolios...meaning they don't really care all that much. If it happens it happens...if it doesn't it will be hard to even find on their balance sheets.
Click to expand...
Yes but biotech has been in the dumps for past few years. Losses now get noticed and add up. It’s not the go go years for biotech. Seals take longer and they are few and far bw. This year was supposed to be big year for m and a but not so much
 




anonymous said:
Yes but biotech has been in the dumps for past few years. Losses now get noticed and add up. It’s not the go go years for biotech. Seals take longer and they are few and far bw. This year was supposed to be big year for m and a but not so much
Click to expand...
This is far too small of a fish for the institutional investors to care about. They have these losses baked in to their overall strategy. Total numbers game for them. They know X amount of these companies will hit and Y amount will not. They are not going to throw energy and resources at KPTI. They would have long ago if they thought it mattered. We are on our own, fingers crossed the data reads out and we have the money to launch. If not we will get bought on the cheap.
 








Top Bottom
Back
Quote